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Abstract
Background/Aim. In some clinical forms of human Campy-
lobacter infections, such as prolonged diarrhea or associated
with postinfections sequels, antibacterial treatment is neces-
sary. The aim of the present study was to evaluate the antimi-
crobial susceptibility of thermophilic Campylobacter strains iso-
lated from patients with diarrhea, as well as from patients with
diarrhea followed by postinfections sequels, to drugs used in
the therapy of enterocolitis, and to nalidixic acid used in labo-
ratory identification and differentiation of thermophilic Cam-
pylobacter spp. Methods. We studied the antimicrobial suscep-
tibility profiles of 131 Campylobacter strains isolated from pa-
tients with diarrhea (122 strains), diarrhea associated with
rheumatic disorders (8 strains), and one strain isolated from a
patient with Guillain-Barré Syndrome following Campylobacter
enterocolitis. Susceptibility testing to erythromycin, gentami-
cin, tetracycline, chloramphenicol, ciprofloxacin and nalidixic
acid was performed by the agar dilution method. Results. In
the strains we investigated, resistance to gentamicin and chlor-
amphenicol was not recorded, whereas a low rate of strains re-
sistant to erythromycin (2.4%), a higher prevalence of strains
resistant to tetracycline (9.9%), and a high level of resistance to
ciprofloxacin (29.8%) and nalidixic acid (33.3%) were regis-
tered. All strains resistant to nalidixic acid were also resistant
to ciprofloxacin. In addition, there was no difference in the
occurrence of resistance between strains isolated from patients
with diarrhea as compared to those isolated from patients with
diarrhea followed by postinfection disorders. Conclusion.
The fact that the most of Campylobacter strains were sensitive to
erythromycin and all to gentamicin, makes erythromycin an
antibiotic of choice in the treatment of Campylobacter diarrhea
and gentamicin when parenteral therapy should be adminis-
tered. Resistance to tetracycline and, especially, ciprofloxacin,
necessitates antibiotic susceptibility testing.
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Apstrakt
Uvod/Cilj. Kod nekih kliničkih oblika infekcije ljudi ter-
mofilnim kampilobakterima, kao što su prolongirana dija-
reja ili pojava postinfektivnih sekvela, neophodna je pri-
mena antibakterijske terapije. Cilj ovog rada bio je ispiti-
vanje osetljivosti termofilnih kampilobaktera na antibiotike
koji se primenjuju u terapiji enterokolitisa, kao i na nalidik-
sinsku kiselinu koja se primenjuje u identifikaciji i diferen-
cijaciji termofilnih kampilobaktera. Metode. Ispitivan je
profil osetljivosti 131 soja termofilnih kampilobaktera
izolovanih kod bolesnika sa dijarejom (122 izolata), kod
bolesnika sa dijarejom reumatskim tegobama (8 izolata),
kao i kod bolesnika sa Guillain-Barré sindromom posle
enterokolitisa izazvanog kampilobakterom (jedan izolat).
Osetljivost na eritromicin, gentamicin, tetraciklin, hloram-
fenikol, ciprofloksacin i nalidiksinsku kiselinu testirana je
agar dilucionom metodom. Rezultati. Kod ispitivanih so-
jeva nije zabeležena rezistencija na gentamicin i hloramfe-
nikol, dok je mali procenat sojeva bio rezistentan na erit-
romicin  (2,4%), a nešto viši na tetraciklin (9,9%). Na cip-
rofloksacin ispoljen je visok procenat rezistencije (29,8%)
kao i na nalidiksinsku kiselinu (33,3%). Svi sojevi rezis-
tentni na nalidiksinsku kiselinu bili su istovremeno rezis-
tentni i na ciprofloksacin.  Nije bilo razlike u pojavi rezis-
tencije kod izolata koji su doveli samo do dijareje i kod
onih koji su izazvali dijareju praćenu postinfektivnim
smetnjama. Zaključak. Činjenica da je većina sojeva bila
osetljiva na eritromicin, a svi sojevi osetljivi na gentamicin,
čini eritromicin antibiotikom izbora u lečenju enterokoliti-
sa izazvanog kampilobakterom, a gentamicin antibiotikom
koji se može primenjivati kada je neophodna parenteralna
terapija. Otpornost na tetraciklin i, naročito, ciprofloksacin
ukazuje na neophodnost testiranja osetljivosti kampiloba-
ktera.
Ključne reči:
lekovi, rezistesncija bakterija; kampilobakter infekcije;
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Introduction
Although human Campylobacter enterocolitis is often a
self-limiting disease, treatment is necessary in illness with
severe symptoms, prolonged disease, in immunocomprom-
ised patients and in patients with chronic sequels, such as
Guillain-Barré syndrome (GBS) 
1. In the therapy of Campy-
lobacter enterocolitis, macrolides and quinolones are very ef-
fective 
2, 3. However, reports on resistance to erythromycin
and also increasing Campylobacter resistance to quinolones
may pose a threat to efficient therapy 
4, 5. In addition, the rate
of sensitivity to drugs recommended for therapy differs be-
tween different geographic regions
 6.
The aim of the present study was to evaluate the anti-
microbial susceptibility of thermophilic Campylobacter
strains isolated from patients with diarrhea, as well as from
patients with diarrhea followed by postinfections sequels,
against drugs used in the therapy of enterocolitis, and to
nalidixic acid used in laboratory identification and differen-
tiation of thermophilic Campylobacter spp.
Methods
We investigated antimicrobial susceptibility of thermo-
philic  Campylobacter strains isolated at the Institute for
Public Health, the town of Niš, Serbia, in 2002 and 2003
from the stool of patients with diarrhea (n = 122) and diar-
rhea followed by rheumatic disorder (n = 8) in clinic and
outclinic patients in Niš. We also included a strain of Cam-
pylobacter jejuni associated with GBS isolated at the Repub-
lic Institute for Public Health, Belgrade. A total of 131
strains was thus included in the study.
Strains were isolated on Columbia agar base supple-
mented with 5% sheep blood and antibiotics (cefoperazone
1.5 g/L, colistin 10
6 U, vancomycin 1 g/L, amphotericin B
0.2 g/L), (bioMérieux, Marcy l’Etoile, France), following in-
cubation in a jar under microaerobic conditions (Gas gener-
ating system “Torlak”, Belgrade, Serbia), at 42º C, 48 hours.
Identification to the level of genus was made using colony
morphology, Gram staining (“gull wings”, S- or spiral-
shaped bacteria), oxidase and catalase tests. Strains were
stored at –20º C in a glucose broth supplemented with 5%
horse serum until susceptibility testing was performed.
Strains grown after 48 hours of incubation at 37º C on
Columbia agar base (bioMérieux, Marcy l’Etoile, France)
with 5% defibrinated horse blood under microaerophilic
conditions described above were resuspended in sterile saline
to obtain a density of 0.5 on a McFarland scale. Susceptibil-
ity testing was performed using the agar dilution method to
erythromycin, gentamicin, tetracycline, chloramphenicol,
ciprofloxacin and nalidixic acid. Pure substances of antibi-
otics were purchased from the manufacturer (“Galenika”,
Belgrade). Erythromycin and chloramphenicol were sus-
pended in 95% ethanol, gentamicin in phosphate-buffered
saline (PBS) (pH 8), tetracycline in distilled H2O, ciproflox-
acin in PBS (pH6) and nalidixic acid in 1N NaOH for stock
dilutions. They were prepared as serial dilutions, and added
to agar base at 50º C in 90 mm agar plates.
One mL of bacterial suspension with a density of 10
5
colony-forming cells (CFU) was cultured in a microaerobic
atmosphere for 48–72 hours on Columbia agar supplemented
with 5% defibrinated horse blood and the appropriate antibi-
otic, in serial dilutions, for minimal inhibitory concentration
(MIC) determination with the concentrations (mg/L) ranging
for erythromycin, gentamicin, ciprofloxacin, tetracyline,
chloramphenicol, and nalidixic acid in intervals 0.12–4,
0.25–8, 0.25–16, 0.25–16, 2–16, 4–64, respectively.
A minimal inhibitory concentration was defined as the
lowest concentration producing no visible growth.
As no official recommendations for breakpoints exist,
we used from the literature data for erythromycin
 4 mg/L 
7,
and for gentamicin and tetracycline, 8 mg/L, cholarampheni-
col 16 mg/L, ciprofloxacin 4 mg/L, nalidixic acid 32 mg/L.
We used MIC interpretative standards for Enterobacteria-
ceae
 8.
Campylobacter jejuni NCCLS 11951 and Staphylococ-
cus aureus ATCC 29213 were used as control for growth.
A multiresistant strain was defined as a strain resistant
to three or more antibiotics.
In order to determine the difference in frequency of re-
sistant strains occurring in the two groups of patients,
Fisher’s exact test was performed. Statistical calculation was
performed using a standard statistical program (EpiInfo ver
6.04).
Results
By using the agar dilution method, we detected antimi-
crobial resistance in 47 strains: to one antibiotic in 32 strains,
to two in 13 strains and to three in two strains. The results of
the susceptibility testing, along with the values of MIC50 and
MIC90, are presented in Table 1.
The results showing the MIC distribution for the six
antibiotics are presented in Table 2.
Table 1
Susceptibility of thermophilic Campylobacter spp. strains to selected antibiotics
Antibiotics No of investigated
strains
MIC* range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Resistance
(%)
Erythromycin 123 ≤0.12–2.0 0.5 1.0 2.4
Gentamicin 126 ≤ 0.25–4.0 0.5 1.0 0
Tetracycline 131 ≤ 0.25–≥ 16 ≤ 0.5 8.0 9.9
Ciprofloxacin 131 ≤ 0.25–16 ≤ 0.25 8.0 29.8
Nalidixic acid 36 ≤ 4.0–≥ 64 8.0 ≥ 64 33.3
Chloramphenicol 130 ≤ 2–16 ≤ 4.0 8.0 0
*minimal inhibitory concentrationStrana 524 VOJNOSANITETSKI PREGLED Volumen 66, Broj 7
Miljković-Selimović B, et al. Vojnosanit Pregl 2009; 66(7): 522–526.
Overall, resistance was recorded for erythromycin, tet-
racycline, ciprofloxacin and nalidixic acid activity in 3
(2.4%), 13 (9.9%), 39 (29.8%), and 12 (33.3%) of the inves-
tigated strains, respectively.
When strains associated with postinfections sequels
were selected, MIC50 and MIC90 (mg/L) for erythromycin
were 0.25 and 0.5, for gentamicin 1 (both values), for tetra-
cycline 0.5 and 4, for chloramphenicol 2 and 4, and for cip-
rofloxacin 0.25 and 8, respectively.
In strains isolated from patients with diarrhea only,
MIC50 and MIC90 were not changed as compared with val-
ues obtained for all investigated strains. Minimal inhibitory
concentrations (mg/L) for the strain isolated from the pa-
tient with GBS were 0.12 for erythromycin, 2 for chloram-
phenicol, 0.5 for ciprofloxacin, and 1 for tetracycline and
gentamicin.
A closer investigation of strains isolated from diarrhea
associated with postinfections sequels (patients with rheu-
matic disorders and GBS) showed resistance to two antibi-
otics: one strain was resistant to tetracycline (11%) and three
strains to ciprofloxacin (33%). Resistance to erythromycin,
chloramphenicol and gentamicin was not recorded. The
strain isolated from the patient with GBS was susceptible to
all antibiotics tested.
When the frequencies of detected resistance to antibi-
otics in the group of strains isolated from patients with diar-
rhea and from patients with diarrhea complicated with rheu-
matic or neurological disorders were compared, no differ-
ences were found (Fisher’ exact test p = 1.00) for erythromy-
cin, tetracycline and ciprofloxacin. Since there was no re-
corded resistance to gentamicin and chloramphenicol in both
investigated groups, statistical analysis was not performed
for those antibiotics.
Discussion
Depending on the geographic localization, the success
of treating Campylobacter spp. infection with drugs recom-
mended for the therapy may differ considerably. The present
susceptibility testing of strains isolated in the town of Niš,
Serbia, revealed occurrence of antimicrobial resistance to
erythromycin, ciprofloxacin, tetracycline and nalidixic acid.
All strains were sensitive to gentamicin and chlorampheni-
col. Higher percentage of resistant strains was proved in the
study conducted in north Indian rural community – antibiotic
resistance of Campylobacter species was as follows: cipro-
floxacin 71.4%, tetracycline 26.5%, furazolidine 14.3%,
gentamicin 10.2% and erythromycin 6.1%; 30.6% of strains
were multidrug resistant
 9. In the study conducted in Poland,
the highest resistance was observed for ciprofloxacin (more
than 40%), followed by ampicillin, and tetracycline, with
significant resistance increase to tetracycline between 2003
and 2005
 10.
The growth of 50 and 90% of our isolates was inhibited
by erythromycin concentrations of 0.5 and 1 mg/L, respec-
tively. In a Finnish study on domestic and foreign strains of
thermophilic Campylobacter strains, MIC50 and MIC90 val-
ues were 1 and 2 μg/ml for domestic strains, whereas the
values for foreign strains were 1 and 4 μg/ml, respectively
 11.
At the breakpoint of MIC ≥ 0.4 mg/L, we detected strains re-
sistant to erythromycin in 2.4% of isolates. That fact under-
lines the possibility of an increasing prevalence of strains re-
sistant to erythromycin in the future.
In a comprehensive study published in Spain in 1994,
resistance to erythromycin was detected in only 3.2% of
strains, with MIC of ≥ 4 μg/ml, while later studies reported
an increase of strains resistant to erythromycin 
7, 12. In the
study conducted in the Netherlands, resistance to erythromy-
cin increased from 1.9% (in their wide 2001) to 2.7% (in
2004)
 13. In Crete, 14.9% of thermophilic Campylobacter
spp. strains were resistant to erythromycin
 14. In some re-
ports, an increasing resistance to macrolides (50%) seems to
be a real threat; however, other studies report on quite low or
absent resistance rates to erythromycin 
15.
Values of MIC50 and MIC90 for gentamicin in our
strains were 0.5 and 1 mg/L, respectively. Our strains did not
exhibit resistance to gentamicin (MIC ranged from ≤ 0.25 to
4 mg/L). In strains studied in Germany MIC50 and MIC90
were 2, without detection of resistant strains at the break-
point of MIC ≥ 16 mg/L 
16. In the Spanish study referred
above, 1% of strains investigated were resistant to gentami-
cin 
7. In Crete, resistance was detected in 2.3% of Campylo-
bacter spp. isolates
 14.
In this study, MIC50 and MIC90 (mg/L) of tetracycline were
≤ 0.5 and 8, respectively, and resistance to tetracycline was seen
in 10% of the strains, at the breakpoint of 8 mg/L. For the strains
isolated in Germany, MIC50 and MIC90 (mg/L) were 0.06 and
16, respectively, with resistant strains occurring in 13.5% of
isolates at the same breakpoint 
16. Resistance to tetracycline was
recorded in the Spanish study in 21.2% of strains
 8.
In this study, MIC50 and MIC90 (mg/L) of ciprofloxacin
were  ≤ 0.25 and 8.0, respectively. In addition, 29.8% of
Table 2
Minimal inhibitory concentrations (MICs) distribution of antibiotics tested among thermophilic Camylobacter spp. strains
MICs distribution (%) Antibiotics No of strains 0.12 0.25 0.5 1 2 4 8 16 32 64 (mg/L)
Erythromycin 123 12.2 33.3 37.4 13.8 0.8| *2.4 – – – –
Gentamicin 126 –
†6.3 57.1 29.4 3.2 4.0 –| – – –
Tetracycline 131 –
†14.5 45 18.3 1.5 6.9 3.8|
‡9.9 – –
Chloramphenicol 130 – – – –
§40.8 45.4 7.7 6.2 | – –
Ciprofloxacin 131 –
†55.0 9.9 1.5 3.1| 13.7 11.5
‡4.6 – –
Nalidixic acid 36 – – – – –
||47.2 19.4 0 0|
¶33.3
*MIC(mg/L) ≥ 4; 
†MIC ≤ 0.25; 
‡ MIC ≥ 16; § MIC ≤ 2; ||MIC ≤ 4; 
¶MIC ≥ 64
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strains investigated were resistant to ciprofloxacin. One of
the first reports of ciprofloxacin resistance (9%) was in 1991,
in Finland
 17. Since then, the prevalence of strains resistant to
ciprofloxacin has increased several times
 9. In a new Finnish
study, MIC50 and MIC90 for domestically acquired strains
were 0.25 and 0.5 μg/mL, respectively and for imported
strains 1 and 64 μg/mL 
11. Those findings suggest a progres-
sively reduced therapeutic value of ciprofloxacin. A resis-
tance rate of 39% was found in human isolates in a study re-
cently conducted in Austria
 18. In another recent study con-
ducted in Thailand, 90% of strains were resistant to cipro-
floxacin 
15. In Crete, 42.5% of Campylobacter spp. strains
were resistant to ciprofloxacin 
14.
Resistance to quinolones in Campylobacter spp. from
human infections may be related to clinical use, or use of
fluoroquinolones in animal husbandry, or both
 19. A more
thorough investigation of this problem is necessary to prevent
its increase. A study conducted in England and Wales
 20 rec-
ommended that both veterinary and clinical use should be re-
considered and that fluoroquinolone antibiotics should be used
only to treat serious infections requiring hospital admission.
Also, using antibiotics in a month before the onset is the risk
factor for acquering a ciprofloxacin-resistant strain of Cam-
pylobacter
 21. Resistance rates increased with increasing ur-
banisation, too
 13. Increased resistance to macrolide and
quinolone antibiotics poses major risks for treatment failure 
22.
We detected a relatively high proportion of resistance to
nalidixic acid. Resistance to nalidixic acid in both Campilo-
bacter jejuni and Campilobacter coli strains was observed
during preliminary identification. All of the strains, which
were resistant to nalidixic acid, were simultaneously resistant
to ciprofloxacin.
This study did not detect strains resistant to chloram-
phenicol. In the study conducted in Spain in 1994 resistance
to chloramphenicol occurred in 2.6 % of isolates 
7. In strains
isolated in Crete, Greece, 7.9% of investigated strains were
resistant to that antibiotic
 14. In England and Wales, resis-
tance to chloramphenicol was recorded in 5.4 % of investi-
gated strains at the breakpoint of 8 mg/L
 20.
Since we have detected two strains that were simulta-
neously resistant to quinolones (ciprofloxacin and nalidixic
acid) and tetracycline, we can not discuss the presence of
multiple resistance in our strains. Multiple resistance in
Campylobacter can occur, but is usually seen in animal iso-
lates
 23. A relatively high rate of multiple resistant strains
(14.8%) was described in Harare, Zimbabwe
 24. In human
isolates, multidrug resistance may include antibiotics impor-
tant for infection treatment, such as erythromycin, tetracy-
cline, and gentamicin or ciprofloxacin, tetracycline, and
erythromycin 
24, 25. The appearance of resistant strains may
be due to less prudent use of antibiotics in veterinary and/or
human practice
 26.
Conclusion
Strains isolated from patients with enterocolitis and en-
terocolitis associated with postinfections sequels expressed a
similar pattern of sensitivity. Low levels of resistance to
erythromycin makes it as the antibiotic of choice in the
treatment of diarrhea or in diarrhea complicated with post in-
fections sequels. When parenteral therapy should be in-
cluded, gentamicin is also a drug of choice. Resistance to tet-
racycline and fluoroquinolones, ciprofloxacin, necessitates
sensitivity testing. Resistance to nalidixic acid diminished its
value in preliminary identification, but in our strains, it was a
marker of resistance to ciprofloxacin. Further investigation
should be considered in Serbia in the future.
Acknowledgments
We thank our colleague, Dr Olga Morić (Republic In-
stitute of Public Health, Belgrade, SRB) for providing a
Campylobacter jejuni strain associated to GBS. This investi-
gation was a part of the project “The role of Campylobacter
jejuni in etiology of some autoimmune diseases, especially
Guillain-Barré Syndrome” (No 1612) and was supported by
the Ministry of Science, Republic of Serbia.
REFERENCES
1.  Doyle MP, Jones DM. Foodborne transmission and antibiotic re-
sistance of campylobacter jejuni. In: Nachamkin I, Blaser
MJ,Tompkins LS, editors. Campylobacter jejuni: current status
and future trends. Washington: DC, American Society for Mi-
crobiology; 1992. p. 45–8.
2.  Vanhoof R. Suspectibility of campylobacter to antimicrobial ag-
nets. In: Butzler JP, editor. Campylobacter infection in man and
animals. Florida: Boca Raton, CRC Press; 1984. p. 77–86.
3.  Mikhail IA, Bourgeois AL, Hyams KC, Podgore JK, Lissner CR,
Walz S. In vitro activity of ciprofloxacin compared to tri-
methoprim-sulfamethoxazole against Sampylobacter spp.
Shigella spp. and Enterotoxigenic Escherichia coli causing
travellers' diarrhea in Egypt. Scand J Infect Dis 1987; 19(4):
479–81.
4.  Taylor DN, Blaser MJ, Echeverria P, Pitarangsi C, Bodhidatta L,
Wang WL. Erythromycin-resistant Campylobacter infections
in Thailand. Antimicrob Agents Chemother 1987; 31(3)
:438–42.
5.  Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Hu-
man campylobacteriosis in developing countries. Emerg Infect
Dis 2002; 8(3): 237–44.
6.  Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin
I. Quinolone and macrolide resistance in Campylobacter jejuni
and C. coli: resistance mechanisms and trends in human iso-
lates. Emerg Infect Dis 2001; 7(1): 24–34.
7.  Reina J, Ros MJ, Serra A. Susceptibilities to 10 antimicrobial
agents of 1220 Campylobacter strains isolated from 1987 to
1993 from feces of pediatric patients. Antimicrob Agents
Chemother 1994; 38(12): 2917–20.
8.  National Committee for Clinical Laboratory Standards. Performance
standards for antimicrobial disk susceptibility tests. Approved
standard M2-A6. Wayne, Pa: National Committee for Clinical
Laboratory Standards; 1997.
9.  Jain D, Sinha S, Prasad KN, Pandey CM. Campylobacter species
and drug resistance in a north Indian rural community. Trans
R Soc Trop Med Hyg 2005; 99(3): 207–14.Strana 526 VOJNOSANITETSKI PREGLED Volumen 66, Broj 7
Miljković-Selimović B, et al. Vojnosanit Pregl 2009; 66(7): 522–526.
10. Rozynek E, Dzierzanowska-Fangrat K, Korsak D, Konieczny P,
Wardak S, Szych J et al. Comparison of antimicrobial resistance
of Campylobacter jejuni and Campylobacter coli isolated from
humans and chicken carcasses in Poland. J Food Prot 2008;
71(3): 602–7.
11. Rautelin H, Vierikko A, Hänninen ML, Vaara M. Antimicrobial
susceptibilities of Campylobacter strains isolated from Finnish
subjects infected domestically or from those infected abroad.
Antimicrob Agents Chemother 2003; 47(1): 102–5.
12. Padungton P, Kaneene JB. Campylobacter spp in human, chick-
ens, pigs and their antimicrobial resistance. J Vet Med Sci
2003; 65(2): 161–70.
13. van Hees BC, Veldman-Ariesen MJ, de Jongh BM, Tersmette M, van
Pelt W. Regional and seasonal differences in incidence and an-
tibiotic resistance of Campylobacter from a nationwide sur-
veillance study in The Netherlands: an overview of 2000-2004.
Clin Microbiol Infect 2007; 13(3): 305–10.
14. Maraki S, Georgiladakis A, Tselentis Y, Samonis G. A 5-year study
of the bacterial pathogens associated with acute diarrhoea on
the island of Crete, Greece, and their resistance to antibiotics.
Eur J Epidemiol 2003; 18(1): 85–90.
15. Bodhidatta L, Vithayasai N, Eimpokalarp B, Pitarangsi C, Serichan-
talergs O, Isenbarger DW. Bacterial enteric pathogens in children
with acute dysentery in Thailand: increasing importance of
quinolone-resistant Campylobacter. Southeast Asian J Trop
Med Public Health 2002; 33(4): 752–7.
16. Bartelt E, Vogt P, Luber P. Antimicrobial resistance of cam-
pylobacter spp. Isolated in 1998 in Germany from broilers,
pigs and cattle and from human stool samples. In: Hacker J.
editor. Proceedings of the Twelfth International Workshop
on Campylobacter, Helicobacter and Related Organisms,
2003 September 4–11; Denmark: Arhus. In J Med Micr 2003.
p. 39.
17. Rautelin H, Renkonen OV, Kosunen TU. Emergence of fluoro-
quinolone resistance in Campylobacter jejuni and Campylo-
bacter coli in subjects from Finland. Antimicrob Agents Che-
mother 1991; 35(10): 2065–9.
18. Hein I, Schneck C, Knögler M, Feierl G, Plesss P, Köfer J, et al.
Campylobacter jejuni isolated from poultry and humans in Sty-
ria, Austria: epidemiology and ciprofloxacin resistance. Epi-
demiol Infect 2003; 130(3): 377–86.
19. Hamer DH, Gill CJ. From the farm to the kitchen table: the
negative impact of antimicrobial use in animals on humans.
Nutr Rev 2002; 60(8): 261–4.
20. Thwaites RT, Frost JA. Drug resistance in Campylobacter jejuni,
C coli, and C lari isolated from humans in north west England
and Wales, 1997. J Clin Pathol 1999; 52(11): 812–4.
21. Gallay A, Bousquet V, Siret V, Prouzet-Mauléon V, Valk H,
Vaillant V, et al. Risk factors for acquiring sporadic Campylo-
bacter infection in France: results from a national case-control
study. J Infect Dis 2008; 197(10): 1477–84.
22. Samie A, Ramalivhana J, Igumbor EO, Obi CL. Prevalence,
haemolytic and haemagglutination activities and antibiotic sus-
ceptibility profiles of Campylobacter spp. isolated from human
diarrhoeal stools in Vhembe District, South Africa. J Health
Popul Nutr 2007; 25(4): 406–13.
23. Randall LP, Ridley AM, Cooles SW, Sharma M, Sayers AR,
Pumbwe L, et al. Prevalence of multiple antibiotic resistance in
443 Campylobacter spp. isolated from humans and animals. J
Antimicrob Chemother 2003; 52(3): 507–10.
24. Simango C, Nyahanana M. Campylobacter enteritis in children in
an urban community. Cent Afr J Med 1997; 43(6): 172–5.
25. Ledergerber U, Regula G, Stephan R, Danuser J, Bissig B, Stärk KD.
Risk factors for antibiotic resistance in Campylobacter spp.
isolated from raw poultry meat in Switzerland. BMC Public
Health 2003; 3: 39.
26. Abstracts of the 11th International Workshop on Campylo-
bacter, Helicobacter and related Organisms. September 1–5,
2001. Germany: Freiburg; Int J Med Microbiol 2001; 291
Suppl 31: 1–168.
The paper received on August 13, 2008.